MiMedx Group Signs Agreement With Regen Lab USA For Distribution Of RegenKit-Wound Gel In U.S.

Benzinga · 3d ago

MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States.

RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors, functional platelets, plasma proteins, and cellular nutrients in a natural fibrin scaffold. The fully autologous solution adds a differentiated option to the Company's Advanced Wound Care portfolio and is backed by multiple published studies evaluating its effectiveness in treating chronic wounds. RegenKit®-Wound Gel kits, developed by Antoine Turzi and approved by FDA in 2022, are covered nationally by CMS and LCD for the treatment of diabetic chronic wounds under HCPCS code G0465.